ARTV

Artiva Biotherapeutics, Inc.

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

5.1d↑+11.5%

as of 2026-07-31

News Summary

Positive

Artiva strengthened its financial position with a $300M capital raise in May 2026, extending cash runway well into 2027 and supporting advancement of AlloNK toward Phase 3 initiation in H2 2026 for refractory rheumatoid arthritis. The company received FDA RMAT designation for AlloNK in June 2026, a significant regulatory tailwind, while Q2 earnings showed expected elevated R&D spending ($21.9M) consistent with late-stage trial preparation, with a modest EPS beat versus consensus.

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Viking Global	SC 13G	NEW	5.4%	+18.8% vs SPY +24.2% abs	2026-05-18	↗